lung cancer
Polypharmacy in Cancer Not Just an Elder Patient Woe
Polypharmacy is highly prevalent among adults with cancer and multimorbidity, and is associated with high health ...
APRIL 25, 2025
High Rates of Polypharmacy Among Lung Cancer Patients—Even Younger Adults
Polypharmacy is highly prevalent among adults with cancer and multimorbidity, and is associated with high health ...
MARCH 12, 2025
Signals From Lungs of Cancer Patients May Cause Thrombosis
Blood clots appear to form in response to signals from the lungs of cancer patients—not from other organ ...
MARCH 3, 2025
Managing Respiratory Distress Symptoms in People with Lung Cancer
Integrating non-pharmacological interventions with pharmacological management of lung respiratory distress symptoms ...
FEBRUARY 21, 2025
Breakthrough in EGFR-Mutated NSCLC: Rybrevant Plus Lazcluze Extends Overall Survival
The bispecific antibody amivantamab-vmjw (Rybrevant, Janssen/Johnson & Johnson) plus lazertinib (Lazcluze, ...
JANUARY 17, 2025
Randomized Trial Validates Virtual Early Palliative Care for Lung Cancer
Almost 15 years after a randomized study demonstrated that early palliative care improved quality of life (QOL) and ...
AUGUST 2, 2024
Immune-Boosting Strategies Could Prevent Lung Cancer in High-Risk Groups
Recent developments in cancer research have highlighted the vital role of the immune system.
APRIL 29, 2024
Adjunctive Beta-Blockers for Lung Cancer Are Promising but Unproven
Beta-blockers taken as adjunctive therapy for lung cancer appear to increase survival rates and reduce metastases. ...
APRIL 17, 2024
Women’s Lung Cancer Needs ‘Embarrassingly Unaddressed’
Even if they have no history of smoking, women are exposed to unique risk factors, yet they continue to lack ...
APRIL 12, 2024
Stigma Places Additional Emotional Burden on Lung Cancer Patients
Regardless of their smoking history, many lung cancer patients often feel stigmatized, which could affect their ...
APRIL 3, 2024
FDA Grants Tabrecta Regular Approval for Metastatic NSCLC
The FDA granted capmatinib (Tabrecta, Novartis) regular approval for adults with metastatic NSCLC with mutations ...
AUGUST 19, 2022
Enhertu Approved as HER2-Directed Therapy for Certain Lung Cancer Patients
The FDA granted a new indication for trastuzumab deruxtecan-nxki (Enhertu, AstraZeneca/Daiichi Sankyo) to treat ...
AUGUST 12, 2022
